When was CoRISMA founded?

CoRISMA was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is CoRISMA located?

CoRISMA is headquartered in Hamden, United States.

Who is the current CEO of CoRISMA?

Mike Theran of CoRISMA. They have also founded 1 company.

How many employees does CoRISMA have?

As of Jul 01, 2024, the latest employee count at CoRISMA is 5.

Is CoRISMA a funded company?

CoRISMA is a funded company, having raised a total of $28.1M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 2020.

When was the latest funding round of CoRISMA?

CoRISMA's latest funding was a $***** Series A round on Aug 30, 2021, with participation from 1 investor. Its primary sector is Cardiac and Vascular Disorders. In United States, the Cardiac and Vascular Disorders sector has seen $795M in funding in 2026 to date.

Where does CoRISMA rank among its competitors?

CoRISMA ranks 42nd amongst 97 active competitors, of which 57 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was FineHeart, which secured $40.8M in Jan, 2026.

Who are the top competitors of CoRISMA?

CoRISMA's top competitors include CVRx, Impulse Dynamics and Adona Medical. Among them, FineHeart secured the most recent funding round in January, 2026.

CoRISMA - 2026 Company Profile, Team, Funding & Competitors

CoRISMA is a series A company based in Hamden (United States), founded in 2018 by Mike Theran. It operates as a Developer of a therapeutic device to treat patients with heart failure. CoRISMA has raised $28.1M in funding from NIH and Connecticut Innovations. The company has 97 active competitors, including 57 funded and 15 that have exited. Its top competitors include companies like CVRx, Impulse Dynamics and Adona Medical.

Company Details

Developer of a therapeutic device to treat patients with heart failure. The company has developed an implanted transcatheter heart failure system powered with energy transmission technology to treat patients suffering from advanced heart failure.

Website: corismacv.com
Email ID: *****@corismacv.com

Key Metrics

Founded Year

2018

Location

Hamden, United States

Stage

Series A

Total Funding

$28.1M in 2 rounds

Latest Funding Round

Series A, Aug 30, 2021, $*****

Investors

NIH & 2 more

Ranked

42^nd among 97 active competitors

Employee Count

5 as on Jul 01, 2024

Similar Companies

CVRx & 123 more

View CoRISMA's full profile

CoRISMA has raised a total funding of $28.1M over 2 rounds. Its first funding round was on Sep 2020. Its latest funding round was a Series A round on Aug 30, 2021 for $*****. 1 investor participated in its latest round. CoRISMA has 3 institutional investors.

Here is the list of recent funding rounds of CoRISMA:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 30, 2021	3303639	Series A	6197337	9129804	5975017	8246018
Sep 2020	8694154	Seed	4342541	9480663	NIH & 1 more	3902382

Access funding benchmarks and valuations. Sign up today!

View details of CoRISMA's funding rounds and investors

The founders of CoRISMA is Mike Theran. Mike Theran is the CEO of CoRISMA.

Here are the details of CoRISMA's key team members:

Mike Theran: Founder and CEO of CoRISMA.

View details of CoRISMA's Founder profiles and Board Members

CoRISMA's employee count trend

CoRISMA has 5 employees as of Jul 24. Here is CoRISMA's employee count trend over the years:

Uncover CoRISMA's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CoRISMA include CVRx, Impulse Dynamics and Adona Medical. Here is the list of Top 10 competitors of CoRISMA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CVRx 2001, Minneapolis (United States), Public	Developer of implantable technology for hypertension and heart failure	$394M	Johnson & Johnson Innovation – JJDC, New Enterprise Associates ... & 20 others	67/100
2nd	Impulse Dynamics 1998, Marlton (United States), Series F	Provider of implantable device for treatment of chronic heart failure	$685M	Redmile Group, Sands Capital & 16 others	64/100
3rd	Adona Medical 2017, Campbell (United States), Series C	Developer of medical devices for the management of heart failure	$71M	Cormorant Asset Management, The Capital Partnership ... & 7 others	64/100
4th	Element Science 2013, San Francisco (United States), Series C	Wearable therapeutic device for treating sudden cardiac arrest	$193M	Deerfield, Qiming & 4 others	62/100
5th	CorWave 2011, Paris (France), Series C	Developer of implantable blood pumps for the treatment of heart failure	$127M	Seventure Partners, Ysios Capital & 11 others	62/100
6th	SynCardia 2001, Tucson (United States), Public	Artificial heart	$72M	Athyrium Capital Management, SWK Holdings ... & 5 others	60/100
7th	Corvia Medical 2009, Tewksbury (United States), Acquired	Developer of transcatheterally shunt for treating diastolic heart failure disease	$160M	Edwards Lifesciences, Accelmed & 4 others	60/100
8th	Reprieve Cardiovascular 2018, Milford (United States), Series B	Developer of decongestion management solution for acute decompensated heart failure patients	$150M	Deerfield, Sante & 8 others	58/100
9th	FineHeart 2010, Pessac (France), Series C	Developer of an implantable cardiovascular device for treating heart failures	$51.9M	Broadview Ventures, Verve Ventures & 16 others	57/100
10th	Restore Medical 2016, Tel Aviv (Israel), Series B	Catheter-delivered implant for treatment of congestive heart failure	$32M	European Commission, Pitango & 3 others	57/100
42nd	CoRISMA 2018, Hamden (United States), Series A	Developer of a therapeutic device to treat patients with heart failure	$28.1M	NIH, Connecticut Innovations & 1 others	37/100